New hope for rare, aggressive blood cancer: 3-Drug cocktail targets richter transformation

NCT ID NCT05388006

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that develops from chronic lymphocytic leukemia (CLL). The goal is to control the disease and improve survival. About 27 adults with this condition will receive the treatment to see if it stops cancer growth and helps the immune system fight the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Stanford Cancer Institute Palo Alto

    NOT_YET_RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Washington University School of Medicine

    WITHDRAWN

    St Louis, Missouri, 63110, United States